Who is affected by this change?

This affects Independence Blue Cross Oncology providers on Medicare Advantage plans.

When does this change take effect?

This change is effective Jul 1, 2025.

Back to dashboard

Medicare AdvantageCoverageMedium impact

MA08.181a, Zolbetuximab-clzb (Vyloy®)

Independence Blue Cross·Oncology·Pharmacy

Effective date

Jul 1, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

A new Medicare Advantage policy for Zolbetuximab-clzb (Vyloy®) has been updated, effective July 1, 2025. This appears to be a pharmacy-related policy change that may affect coverage, prior authorization, or billing requirements for this specialty oncology medication.

Action Required

Action needed

By July 1, 2025: Review the complete policy MA08.181a at the provided URL to understand specific coverage criteria, prior authorization requirements, or billing changes for Zolbetuximab-clzb (Vyloy®). Update billing protocols and provider notifications as needed based on the full policy details.

Related policy hubs

Independence Blue Cross policies Oncology